Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2641 to 2655 of 8935 results

  1. Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]

    Awaiting development Reference number: GID-TA11458 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [ID6605]

    Awaiting development Reference number: GID-TA11751 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]

    In development Reference number: GID-TA11733 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  4. Neonatal infection: antibiotics for prevention and treatment - update

    In development Reference number: GID-NG10456 Expected publication date:  13 May 2026

    NICE guideline
    In development

  5. Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane [ID6743]

    Awaiting development Reference number: GID-TA11969 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]

    In development Reference number: GID-TA11963 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Fenebrutinib for treating relapsing multiple sclerosis [ID6577]

    Awaiting development Reference number: GID-TA11775 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]

    Awaiting development Reference number: GID-TA11721 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464]

    Awaiting development Reference number: GID-TA11661 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Plozasiran for treating familial chylomicronaemia syndrome [ID6593]

    In development Reference number: GID-TA11793 Expected publication date:  17 September 2026

    Technology appraisal guidance
    In development

  11. Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

    In development Reference number: GID-TA11386 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Highly specialised technology. Comments close 24 February 2026.

    Highly specialised technologies guidance
    In consultation

  13. Ruxolitinib for treating non-segmental vitiligo in people 12 years and over (rapid review of TA1088) [ID6652]: final draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 24 February 2026.

    Technology appraisal guidance
    In consultation

  14. Technologies for the rapid diagnosis of endometriosis

    In development Reference number: GID-HTE10082 Expected publication date:  08 October 2026

    Health technology evaluations
    In development

  15. MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor

    In development Reference number: GID-IPG10441 Expected publication date: TBC

    Interventional procedures guidance
    In development